...
首页> 外文期刊>Medicine. >Pretreatment Neutrophil-to-Lymphocyte Ratio: A Predictor of Advanced Prostate Cancer and Biochemical Recurrence in Patients Receiving Radical Prostatectomy
【24h】

Pretreatment Neutrophil-to-Lymphocyte Ratio: A Predictor of Advanced Prostate Cancer and Biochemical Recurrence in Patients Receiving Radical Prostatectomy

机译:预处理中性粒细胞与淋巴细胞的比率:前列腺癌根治术患者晚期前列腺癌和生化复发的预测指标。

获取原文

摘要

The pretreatment neutrophil-to-lymphocyte ratio (NLR) is reportedly associated with the clinical outcomes of many cancers. However, it has not been widely investigated whether the pretreatment NLR is associated with the pathological characteristics of prostate cancer (PCa) and biochemical recurrence in PCa patients receiving radical prostatectomy (RP). In this cohort study, a total of 1688 PCa patients who had undergone RP were analyzed retrospectively, and a subset of 237 of these patients were evaluated to determine the relationship between pretreatment NLR and biochemical recurrence. Patients were divided into a high-NLR group (NLR ≥2.36) and a low-NLR group (NLR < 2.36) according to the pretreatment NLR. The association between the pretreatment NLR and pathological stage and lymph node involvement was evaluated using logistic regression analysis. Time of biochemical recurrence was determined using the Kaplan–Meier method. Cox's proportional hazard regression model was used to compare the time of biochemical recurrence between the groups. As compared with patients in the low-NLR group, those in the high-NLR group had an increased risk of pT3–4 disease (odds ratio (OR), 1.883; 95% confidence interval (CI), 1.419–2.500; P < 0.001), and a 1.7-fold increased risk of lymph node involvement (OR, 1.685; 95% CI, 1.101–2.579; P = 0.016). For the subset of 237 patients, those with a high NLR showed a significantly shorter median biochemical recurrence-free survival time (51.9 months) than those with a low NLR (76.5 months; log-rank test, P = 0.019). However, multivariate analysis indicated that the NLR was not an independent predictor of biochemical recurrence (hazard ratio, 1.388; 95% CI, 0.909–2.118; P = 0.129). Our findings suggest that the pretreatment NLR may be associated with pathological stage and lymph node involvement in PCa patients receiving RP, and that PCa patients with a high NLR may have a higher rate of biochemical recurrence following RP than those with a low NLR.
机译:据报道,中性粒细胞与淋巴细胞的预处理比例(NLR)与许多癌症的临床结局有关。然而,尚未进行广泛的研究,以探讨接受NLR预处理是否与接受根治性前列腺切除术(RP)的PCa患者的前列腺癌(PCa)的病理特征和生化复发有关。在该队列研究中,回顾性分析了总共1688例接受RP的PCa患者,并对其中237例患者的一部分进行了评估,以确定治疗前NLR与生化复发之间的关系。根据治疗前的NLR,将患者分为高NLR组(NLR≥2.36)和低NLR组(NLR <2.36)。使用逻辑回归分析评估了治疗前NLR与病理分期和淋巴结受累之间的关联。使用Kaplan-Meier方法确定生化复发的时间。使用Cox比例风险回归模型比较两组之间生化复发的时间。与低NLR组的患者相比,高NLR组的患者患pT3-4疾病的风险增加(几率(OR)为1.883; 95%置信区间(CI)为1.419-2.500; P < 0.001),淋巴结受累的风险增加了1.7倍(OR为1.685; 95%CI为1.101–2.579; P = 0.016)。在237例患者中,具有较高NLR的患者的中位无生化无复发生存时间(51.9个月)明显低于具有较低NLR的患者(76.5个月;对数秩检验,P = 0.019)。但是,多变量分析表明,NLR不是生化复发的独立预测因子(危险比:1.388; 95%CI:0.909-2.118; P = 0.129)。我们的研究结果表明,在接受RP的PCa患者中,治疗前NLR可能与病理分期和淋巴结受累有关,并且NRP较高的PCa患者在RP后的生化复发率可能比NLR低的PCa患者高。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号